Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure

Annals of Surgical Oncology

Volumn 15, Issue 1, 2008, Pages 219-226

  Boige, Valérie ^a   Malka, David ^a   Elias, Dominique ^a   Castaing, Marine ^a   De Baere, Thierry ^a   Goere, Diane ^a   Dromain, Clarisse ^a   Pocard, Marc ^a   Ducreux, Michel ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

5 fluorouracil; Colorectal cancer; Liver metastases; Oxaliplatin; Regional chemotherapy

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ABDOMINAL PAIN; ADULT; AGED; ALLERGY; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COLORECTAL CANCER; DIARRHEA; DRUG DOSE REDUCTION; FEMALE; FEVER; HUMAN; INFECTION; LIVER METASTASIS; MALE; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NEUTROPHIL COUNT; PARESTHESIA; PERIPHERAL NEUROPATHY; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT FAILURE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEASIBILITY STUDIES; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; INFUSIONS, INTRAVENOUS; LEUCOVORIN; LIVER NEOPLASMS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 38049164083     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-007-9581-7     Document Type: Article

References (28)

1. Breedis C, Young C. The blood supply of neoplasm in the liver. Am J Pathol 1954; 30:969-74
2. Chen GHG, Gross JF. Intra-arterial infusion of anticancer drugs: theoretic aspects of drug delivery and review of responses. Cancer Treat Rep 1980; 64:31-40
3. Meta-Analysis group in Cancer. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst 1996; 88:252-8
4. Kerr DJ, McArdle CS, Ledermann J, et al. Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. Lancet 2003; 361:368-73
5. Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229-37
6. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22:23-30
7. Colucci G, Gebbia V, Paoletti G, et al. Phase III randomised trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 2005; 23:4866-75
8. Köhne CH, van Cutsem E, Wils J, et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 2005; 23:4856-65
9. Rothenberg ML, Oza AM, Bigelow RH, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003; 21:2059-69
10. Ulrich-Pur H, Kornek GV, Fiebiger W, et al. Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy. Ann Oncol 2001; 12:1269-72
11. Park SH, Sung JY, Han SH, et al. Oxaliplatin, folinic acid and 5-fluorouracil (FOLFOX-4) combination chemotherapy as second-line treatment in advanced colorectal cancer patients with irinotecan failure: a Korean single-center experience. Jpn J Clin Oncol 2005; 35:531-5
12. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-45
13. Kemeny NE, Niedzwiecki D, Hollis DR, et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 2006; 24:1395-1403
14. Ducreux M, Ychou M, Laplanche A, et al. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Fédération Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol 2005; 23:4881-7
15. Conroy T, Gory-Delabaere G, Adenis A, et al. Clinical practice guideline: (2003) update of Standards, Options et Recommendations for first line palliative chemotherapy in patients with metastatic colorectal cancer (summary report). Bull Cancer 2004; 91:759-68
16. Levi F, Perpoint B, Garufi C, et al. Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. Eur J Cancer 1993; 29A:1280-4
17. WHO Handbook for Reporting Results of Cancer Treatment. World Health Organization, Geneva, Switzerland, 1979
18. Simon R. Optimal two-stage designs for phase II clinical trials in oncology. Control Clin Trials 1989; 10:1-10
19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Assoc 1958; 53:457-81
20. Kemeny N, Jarnagin W, Paty P, et al. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol 2005; 23:4888-96
21. Kemeny N, Gonen M, Sullivan D, et al. Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer. J Clin Oncol 2001; 19:2687-95
22. Rougier P, Laplanche A, Huguier M, et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol 1992; 10:1112-8
23. Kern W, Beckert B, Lang N, et al. Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer. Ann Oncol 2001; 12:599-603
24. Dzodic R, Gomez-Abuin G, Rougier P, et al. Pharmacokinetic advantage of intra-arterial hepatic oxaliplatin administration: comparative results with cisplatin using a rabbit VX2 tumor model. Anticancer Drugs 2004; 15:647-50
25. van Riel JM, van Groeningen CJ, Kedde MA, et al. Continuous administration of irinotecan by hepatic arterial infusion: a phase I and pharmacokinetic study. Clin Cancer Res 2002; 8:405-12
26. van Riel JM, van Groeningen CJ, de Greve J, Gruia G, Pinedo HM, Giaccone G. Continuous infusion of hepatic arterial irinotecan in pretreated patients with colorectal cancer metastatic to the liver. Ann Oncol 2004; 15:59-63
27. Mancuso A, Giuliani R, Accettura C, et al. Hepatic arterial continuous infusion (HACI) of oxaliplatin in patients with unresectable liver metastases from colorectal cancer. Anticancer Res 2003; 23:1917-22
28. Aldrighetti L, Arru M, Angeli E, et al. Percutaneous versus surgical placement of hepatic artery indwelling catheters for regional chemotherapy. Hepatogastroenterology 2002; 49:513-7